GLP-1 Compounded Medication FDA Safety Alerts (2023-2025)
You’ve seen the news. Counterfeit GLP-1 products online. FDA warning letters to compounding pharmacies. Questions about whether the medication you’re taking actually contains what it says.
The concern is legitimate. But the reality is more nuanced than the headlines suggest.
This page walks through what the FDA has actually found, what it means for patient safety, and how to verify that your compounding pharmacy meets real safety standards. We won’t minimize the risks, and we won’t oversell the reassurance either. You deserve both honesty and clarity.
Counterfeit and Unregulated Products Online: The Biggest Risk
The most significant FDA safety alert issued in recent years focuses on fake and counterfeit GLP-1 products sold online without a prescription.
In 2023 and 2024, the FDA issued multiple broad safety warnings about injectable pens and vials sold through online marketplaces and “research chemical” websites claiming to contain semaglutide[1]. When tested, many contained no active ingredient at all. Others contained undisclosed substances with unknown safety profiles.
These products came from unregulated sources: online marketplaces, overseas suppliers, and “research peptide” retailers that explicitly avoid regulated pharmacy channels.
The FDA’s clear position[2]: consumers should obtain prescription GLP-1 medications only through licensed pharmacies with a valid prescription from a licensed provider.
This distinction matters because it separates the real safety problem (unregulated, counterfeit products sold as “research chemicals”) from the legitimate question of whether compounded medications from licensed pharmacies are safe. They are different risk levels.
FDA Salt-Form Guidance (2024)
In 2024, the FDA issued guidance that caught the compounding industry’s attention[3].
Some compounding pharmacies were preparing semaglutide sodium or semaglutide acetate, salt forms of the drug, rather than semaglutide base. The FDA stated that the salt forms are not equivalent to semaglutide base and raised concerns about potency and bioavailability[4]. The FDA made clear that semaglutide base is the appropriate active pharmaceutical ingredient for compounding under 503A.
What this means for you: if you are using compounded semaglutide, ask your pharmacy which form they are using. Semaglutide base is the appropriate choice. If your pharmacy is using a salt form, that is a quality concern worth discussing with your provider.
Legitimate compounders should be able to answer this question directly and provide documentation of their ingredient sourcing.
FDA Warning Letters to Compounding Pharmacies
Beyond broad safety alerts, the FDA issued warning letters and 483 observations to multiple compounding pharmacies during 2024 and 2025 for specific quality violations[5].
The violations documented in these letters include:
- Inadequate sterility testing and validation
- Incorrect potency verification (medication batches not meeting labeled strength)
- Missing or incomplete certificates of analysis
- Inadequate labeling and batch tracking
- CGMP (Current Good Manufacturing Practice) violations in facility operations
These are not speculative concerns. These are real compliance failures that affect product quality.
The good news: the FDA warning letter database is public and searchable[6]. You can check whether your specific pharmacy has received a warning letter. If your pharmacy has received a warning letter for quality or sterility issues, that is a clear reason to seek care elsewhere.
Adverse Event Reports: What FAERS Shows
The FDA maintains FAERS, the Adverse Event Reporting System, which collects reports of side effects and safety issues related to medications.
For GLP-1 medications, FAERS contains reports of serious adverse events including gastroparesis (stomach paralysis), aspiration, and pancreatitis[7]. Most of the documented serious events are associated with brand-name GLP-1 products (semaglutide and tirzepatide), not specifically with compounded versions.
An important distinction: branded products have FDA-mandated pharmacovigilance[8], meaning the manufacturer actively monitors and reports safety signals to the FDA. Compounded products have no equivalent independent monitoring system. This does not mean compounded products are necessarily less safe, but it does mean there is no systematic FDA-level safety monitoring in place.
What Distinguishes Safe From Unsafe Sources
Red flags are important. So are green flags. Here is what the difference looks like.
Red flags: unsafe or unregulated sources
- Source claims to dispense without a valid prescription, or approves prescriptions automatically after an online questionnaire without provider review
- Sold as “research peptide,” “research chemical,” or “peptide reagent”
- Purchased through general online marketplaces (Amazon, eBay, Facebook Marketplace) without pharmacy verification
- No lot number, batch number, or certificate of analysis available
- Overseas source or shipped from outside the US
- Pricing far below the typical compounded pharmacy range, which can indicate counterfeit or unregulated product
- No response when asked about ingredient sourcing or quality testing
Green flags: legitimate compounding pharmacies
- US-based, state-licensed compounding pharmacy
- Requires valid prescription from a licensed provider
- Provides batch-specific certificate of analysis (COA) on request
- Clearly identifies the API used (semaglutide base, tirzepatide free base)
- PCAB accredited (Pharmacy Compounding Accreditation Board) or 503B FDA registered
- Provides batch number with every shipment
- Responsive to questions about quality testing and ingredient sourcing
- Pricing consistent with market rate for compounded GLP-1s ($200-400/month)
How to Verify Your Pharmacy’s Safety Record
You have agency here. You can verify your pharmacy’s legitimacy yourself.
Step 1: Check your state pharmacy board
Every US state has a pharmacy board that maintains a public database of licensed pharmacies. You can search your pharmacy’s name and license status. An active license is the baseline.
Step 2: Check the FDA warning letter database
Go to FDA.gov and search their warning letter database for your pharmacy’s name. If your pharmacy appears in a warning letter for quality, sterility, or potency issues related to compounded GLP-1s, that is significant. You should discuss this with your provider and consider alternatives.
Step 3: Ask for a certificate of analysis
Request the COA for your specific batch. A legitimate pharmacy will provide it. The COA shows:
- Batch number and date
- Potency testing (verified active ingredient strength)
- Sterility testing (bacterial and fungal growth testing)
- Purity analysis
- Third-party laboratory name
If a pharmacy cannot or will not provide a COA, that is a serious quality concern.
Step 4: Verify PCAB accreditation
The Pharmacy Compounding Accreditation Board (PCAB) maintains a public list of accredited pharmacies[9]. Go to pcabaccreditation.org and search your pharmacy. Accreditation is voluntary but indicates a higher standard of quality control.
Step 5: Confirm prescription requirement
A legitimate pharmacy requires a valid prescription from a licensed provider before dispensing. If you encountered your pharmacy through a source that does not require a prescription, or requires only an online questionnaire without provider evaluation, that is a red flag.
What Transformation Health Does
Transparency about our approach matters.
Transformation Health works exclusively with US-based, state-licensed compounding pharmacies. We do not accept partnerships with overseas suppliers, unregulated retailers, or pharmacies that operate without prescription requirements.
All prescriptions require evaluation by an independent, licensed provider. Your provider reviews your complete health history, current medications, and medical conditions. The provider, not our company, makes the clinical determination of whether a prescription is medically appropriate for you.
Before any medication is dispensed, you receive:
- Clear identification of the medication and API (semaglutide base or tirzepatide free base)
- Batch number
- Access to the certificate of analysis for your specific batch
- Shipping from a licensed US pharmacy
We also include a required disclosure: compounded medications are not FDA-approved. They have not been independently evaluated by the FDA for safety, efficacy, or quality. They differ from commercially available branded medications in ways that matter.
This is not a workaround to FDA oversight. It is a legitimate medical pathway for patients who, after provider evaluation, are candidates for GLP-1 therapy.
What You Should Do Now
If you currently take a compounded GLP-1 medication:
- Confirm your pharmacy is licensed in your state (check your state pharmacy board)
- Search the FDA warning letter database for your pharmacy’s name
- Request your most recent certificate of analysis
- Ask your pharmacy which form of the API they use (semaglutide base, not salt forms)
If you’re evaluating whether to start compounded GLP-1 therapy:
- Work with a provider who conducts a full medical evaluation, not just an online questionnaire
- Ask that provider which compounding pharmacy they work with
- Before filling your first prescription, verify the pharmacy’s license and check the FDA warning letter database
- Request a certificate of analysis for your batch
If you obtained GLP-1 medication online without a prescription, or from an overseas source, the safety risks are real and significant. Discuss alternatives with a provider.
The FDA safety alerts exist because real safety problems occur. But the problems are concentrated in unregulated, counterfeit products and compounders operating without quality controls. Licensed US-based pharmacies with verifiable quality standards represent a different category of risk entirely.
You deserve to know the difference, and you deserve medication from a pharmacy you can verify.
Citations
[1] FDA. “GLP-1 Safety Alerts and Counterfeit Warnings.” https://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements
[2] FDA. “Consumer Alert on Counterfeit GLP-1 Products.” https://www.fda.gov/drugs/drug-safety-and-availability
[3] FDA. “Semaglutide Salt Form Guidance (2024).” https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
[4] FDA. “Compounding Pharmacy Guidance on Active Pharmaceutical Ingredients.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act
[5] FDA. “Warning Letters to Compounding Pharmacies (2024-2025).” https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
[6] FDA. “Warning Letter Database.” https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
[7] FDA. “Adverse Event Reporting System (FAERS).” https://fis.fda.gov/sense/app/d10eg5jd-fa20-40e7-ab00-4d5209e33064/sheet/7ed37e21-54fe-466b-8f5c-4fc28edde77e/state/edit
[8] FDA. “Pharmacovigilance and Safety Monitoring.” https://www.fda.gov/drugs/drug-safety-and-availability
[9] Pharmacy Compounding Accreditation Board. “PCAB Directory.” https://www.pcab.org/
Important: Compounded medications are not FDA-approved products. They are prepared by US-based, state-licensed compounding pharmacies and have not been independently evaluated by the FDA for safety, efficacy, or quality. All prescriptions require evaluation by an independent, licensed healthcare provider. Not all patients will qualify. Results vary by individual.